Ondansetron disintegrating tablets of 8 mg twice a day for 3 days did not reduce the incidence of nausea or vomiting after laparoscopic surgery

European Journal of Anaesthesiology

Volumn 20, Issue 2, 2003, Pages 153-157

  Thagaard, K S ^a   Steine, S ^a   Raeder, Johan ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Analgesia; Antiemetics, ondansetron; Endoscopy, laparoscopy; Pain, pain, postoperative, postoperative complications, postoperative nausea and vomiting

Indexed keywords

CODEINE; DROPERIDOL; FENTANYL; KETOROLAC; LIDOCAINE; METOCLOPRAMIDE; MIDAZOLAM; ONDANSETRON; PARACETAMOL; PLACEBO; PROPACETAMOL; PROPOFOL; REMIFENTANIL; ROCURONIUM;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INCIDENCE; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGHTMARE; PAIN; PATIENT SATISFACTION; POSTOPERATIVE COMPLICATION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; CHOLECYSTECTOMY; DOUBLE-BLIND METHOD; FEMALE; FUNDOPLICATION; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; ONDANSETRON; PAIN, POSTOPERATIVE; POSTOPERATIVE NAUSEA AND VOMITING; QUESTIONNAIRES; TABLETS; TIME FACTORS;

EID: 0037319369     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021503000280     Document Type: Article

References (10)

1. Raeder JC, Mjaland O, Aasbo V, Grogaard B, Buanes T. Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy. Acta Anaesthesiol Scand 1998; 42: 106-110.
2. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87: 1277-1289.
3. VanDenBerg CM, Kazmi Y, Stewart J, et al. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. Am J Health Syst Pharm 2000; 57: 1046-1050.
4. Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES Jr, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 1998; 18: 288-294.
5. Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 1999; 21: 492-502.
6. LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 1999; 11: 340-347.
7. Gan TJ, Franiak R, Reeves J, Hartle AJ. Ondansetron disintegrating tablets (ODT) reduces post-discharge emesis and increases patient satisfaction. In: Abstracts of the Annual Scientific Meeting, 2000. Park Ridge, USA: American Society of Anesthesiologists, 2000: A-34.
8. Apfel CC, Greim CA, Haubitz I, et al. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand 1998; 42: 495-501.
9. Bowhay AR, May HA, Rudnicka AR, Booker PD. A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children. Paediatr Anaesth 2001; 11: 215-221.
10. Pearman MH. Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia 1994; 49 (Suppl): 11-15.